Participation in all clinical trials is voluntary and patients may choose to withdraw from any study at any time. Most of our clinical trials are sponsored by the federally-funded National Institutes of Health (NIH) or pharmaceutical and biotechnology companies. ClinicalTrials.Gov lists these and other clinical trials.

Below is a listing of our studies that are currently enrolling new patients.

Click on the name of the study to be directed to each study-specific page on clinicaltrials.gov

  • Wet AMD (Age Related Macular Degeneration)
    • RGX-314 Sponsored by RegenxBio
      The long-term, stable delivery of this therapeutic protein following a 1 time gene therapy treatment for nAMD could potentially reduce the treatment burden of currently available therapies while maintaining vision with a favorable benefit:risk profile.
    • DAWN
      A previous pilot study demonstrated that commonly available glaucoma drops (dorzolamide-timolol) might decrease the amount of chronic swelling in patient with wet age-related macular degeneration who have been receiving anti-vascular endothelial growth factor (VEGF) injections. This will be a larger study where subjects are randomly assigned to receive the glaucoma drops or a placebo (artificial tears) in order to confirm whether this previous finding is valid.
    • Opthea
      A multicenter, randomized, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.
    • Ophthotech 2007
      To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (nAMD)
    • Optic Sponsored by Adverum Biotechnologies
      ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product developed for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is a serious condition and the leading cause of blindness in the elderly. The available therapies for treating wet AMD require lifelong intravitreal (IVT) injections every 4-12 weeks to maintain efficacy. A one-time administration of ADVM-022 has the potential to treat we AMD by providing durable expression of therapeutic levels of intraocular anti-VEGF protein (aflibercept) and preserving the vision of patients. ADVM-022 is designed to reduce the current treatment burden and the adverse events (AEs) associated with chronic IVT injections.
    • Kodiak Sponsored by Kodiak Services
      This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg.
    • Portal Sponsored by F. Hoffmann-La Roche
      This study will evaluate the long-term safety and tolerability of the Port Delivery System (PDS) with ranibizumab 100 mg/mL with refills administered every 24 weeks (Q24W) for approximately 144 weeks in participants with neovascular age-related macular degeneration (nAMD) who have completed either Phase II Study GX28228 or Phase III Study GR40548.
    • Archway Sponsored by F. Hoffmann-La Roche
      Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor [VA]-masked), active-comparator study designed to assess the efficacy, safety, and pharmacokinetics (PK) of 100mg/ml delivered via the Port Delivery System (PDS) compared with ranibizumab intravitreal injections at 0.5 mg (10 mg/mL) in participants with neovascular age-related macular degeneration (nAMD).
    • Graybug Sponsored by Graybug Vision
      Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor [VA]-masked), active-comparator study designed to assess the efficacy, safety, and pharmacokinetics (PK) of 100mg/ml delivered via the Port Delivery System (PDS) compared with ranibizumab intravitreal injections at 0.5 mg (10 mg/mL) in participants with neovascular age-related macular degeneration (nAMD).
    • Tenaya Sponsored by F. Hoffmann-La Roche
      This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).
    • Lucerne Sponsored by F. Hoffmann-La Roche
      This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).
    • Merlin Sponsored by Novartis
      Thepurpose of this study is to compare safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those nAMD patients with retinal fluid despite frequent anti-Vascular Endothelial Growth Factor (VEGF) injections.
  • Dry AMD (Age Related Macular Degeneration)
    • Ophthotech 2003 Sponsored by Ophthotech
      The objectives of this study are to evaluate the safety and efficacy of intravitreous administration of Zimura when administered in subjects with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD)
    • TOGA Sponsored by the University of Virginia
      Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)
    • Oaks and Derby Sponsored by Apellis Oaks
    • Astellas Sponsored by A.I.R.M
      The purpose of this study during the Dose Escalation stage is to assess the safety and tolerability of 3 ascending doses of ASP7317 in participants with age-related macular degeneration (AMD), of which one dose will be selected for evaluation of efficacy and safety during the Proof of Concept (PoC) stage of the study. The primary purpose of the study during the PoC stage is to assess the safety, tolerability and superiority of ASP7317 at low cells/dose and the selected dose compared to untreated control and acuity (BCVA). This study will also assess safety by incidence of graft failure or rejection with a 13-week regimen of immunosuppression therapy. Efficacy will also be assessed by the differences among ASP7317 at low cells/dose, ASP7317 at the selected dose and the untreated control group in other functional and structural parameters and patient reported outcomes during the PoC stage. During the Extension stage this study will assess the safety and tolerability of ASP7317 at the most efficacious dose from PoC in participants randomized to the untreated control group.
    • Clarity 1 & Clarity 2 Sponsored by Gemini Therapeautics
      A Genetic Screening and Registry Study to Evaluate Long-term Clinical Outcomes and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) Who Are Carriers of High-Risk Genetic Complement Variants Associated with Dry Age-related Macular Degeneration (AMD).
    • Gallego Sponsored by Genetech, Inc.
      This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of RO7171009 administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) compared with sham control.
    • Gryoscope Sponsored by Gyroscope Therapeutics
      An observational study to evaluate the natural progression of dry AMD in genetically defined subjects
    • Boehringer Ingelheim Pharmaceuticals
  • Uveitis
    • MERIT Sponsored by The Must Research Group
      Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (MERIT)
    • Gilead
      The primary objective of this study is to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis in participants failing treatment for active noninfectious uveitis.
    • Lumina Sponsored by Santen
      This is a Phase III study to assess the efficacy and safety of DE-109 440 µg every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye (NIU-PS). There is a 6-month, single-arm, open-label period after completion of the 6-month double-masked, controlled period allows the evaluation of the efficacy and safety of intravitreal injection of DE-109 440 µg every 2 months for longer duration than appropriate for a placebo or sham control.
    • Advise Sponsored by the JHSPH Center for Clinical Trials
      Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNF-α monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, parallel-treatment, comparative effectiveness trial comparing adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in the treatment of non-infectious, intermediate, posterior, and panuveitides.
  • Retinal Vein Occlusion
    • Orion Sponsored by Aerie
      This study will evaluate the safety, tolerability and efficacy of AR-1105 (dexamethasone implant) for the treatment of macular edema (ME) due to retinal vein occlusion (RVO). A more durable intravitreal implant containing a low dose of dexamethasone may result in less frequent retreatments, a potentially lower the incidence of steroid-related side effects without compromising efficacy.
    • Kodiak Sponsored by Kodiak Services
      This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg.
    • Raven Sponsored by Novartis
      The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
    • Raptor Sponsored by Novartis
      The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
  • Diabetic Macular Edema
    • AC Switch
      A DRCR Study – To compare the efficacy of intravitreous aflibercept with intravitreous bevacizumab + deferred aflibercept if needed in eyes with CI DME and moderate vision loss.
    • Kestrel Sponsored by Novartis
      The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
    • Yosemite Sponsored by F. Hoffman-La Roche
      This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).
    • Rhine Sponsored by F. Hoffman-La Roche
      This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME)
    • Kodiak Sponsored by Kodiak Services
      This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg.
    • Dovetail Sponsored by F. Hoffman-La Roche
  • Diabetic Retinopathy
    • Panorama Sponsored by Regeneron
      The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR).
  • Retinitis Pigmentosa
    • Argus
      This post-approval study is being implemented to monitor the use of Argus II System in a larger US population than available within pre-approval studies. An attempt will be made to include all eligible and willing subjects implanted with Argus II System in the United States.
    • AGTC
      This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations. Approximately 30 participants will be enrolled, and 5 dose levels will be evaluated in a dose-escalation format.
  • Lebers Congenital Amaurosis
    • Sanofi
      The primary objective of this study is to evaluate the safety and tolerability of ascending doses of SAR439483 administered as a unilateral subretinal injection in patients with Leber Congenital Amaurosis (LCA) caused by autosomal recessive guanylate cyclase 2D (GUCY2D) mutations (GUCY2D-LCA). The secondary objective is to evaluate the efficacy of ascending doses of SAR439483 administered as a unilateral subretinal injection in patients with GUCY2D-LCA.
    • Extension Study Sponsored by Pro QR
      Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety, tolerability, pharmacokinetic (PK), and efficacy data of QR-110.